A human pancreas contains 1-3 million pancreatic islets (also known as islets of Langerhans) 1,2 . The islets are complex micro-organs that consist of several types of endocrine cells that have a key role in the regulation of whole-body energy metabolism 3 . Insulin is secreted by the β-cells (which comprise 55-75% of the islet cells, depending on the species 4 ); it is the only hormone that lowers blood levels of glucose. Glucagon, the principal hormone in plasma that increases glucose levels, is secreted by the α-cells (making up 20-40% of the islet cells). The δ-cells (comprising ~5% of the islet cells) secrete somatostatin, which inhibits the release of insulin and glucagon. In general, levels of insulin and glucagon vary reciprocally, and the insulin:glucagon ratio determines the balance between anabolism (glucose and lipid storage) and catabolism (glycogen and lipid breakdown and gluconeogenesis) 3
. The combination of lack of insulin and excess glucagon results in the severe metabolic disturbances associated with diabetes mellitus that culminate in hyperglycaemia 5, 6 . Most therapeutic interventions focus on insulin by stimulating its endogenous release (through administering sulfonylureas or glucagonlike peptide 1 (GLP1) agonists), by promoting insulin action (via the administration of insulin sensitizers such as metformin) or by administering exogenous insulin.
A serious and potentially fatal complication of insulin therapy is hypoglycaemia. Up to 10% of insulin-treated patients with diabetes mellitus are estimated to die of iatrogenic hypoglycaemia (iatros is Greek for 'healer' or 'physician') 7 . During the past 30-40 years, α-cells and β-cells have been the focus of much research because of their key roles in diabetes mellitus, and we now have a good understanding of the regulation of insulin secretion 8, 9 . A consensus model for the regulation of glucagon secretion remains to be formulated, but there is extensive information on the α-cell gene expression profile, ultrastructure, electrophysiology and exocytosis 10, 11 . In comparison, the δ-cells have not received as much attention from islet physiologists, and our understanding of the cellular control of somatostatin secretion remains fragmentary. Findings from the past 10 years implicate increased somatostatin signalling as a cause of the reduced counter-regulatory glucagon secretion during insulin-induced hypoglycaemia in animals with diabetes mellitus [12] [13] [14] . Conversely, there is evidence that hyperglucagonaemia in patients with poorly controlled diabetes mellitus can be suppressed by exogenously administered somatostatin [15] [16] [17] . Indeed, somatostatin infusion in patients with type 1 or type 2 diabetes mellitus improves glycaemic control, despite
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the patients requiring less insulin, by reducing glucagon secretion. Accordingly, it was proposed that a long-acting somatostatin agonist might be useful as an adjunct to insulin therapy 18 . Collectively, these observations merit renewed interest in pancreatic δ-cells. Therefore, a review on δ-cell physiology and somatostatin secretion in health and disease is timely. Here, we present a model for the cellular regulation of somatostatin secretion in δ-cells and discuss the crucial role they play in controlling the α-cells and β-cells via inhibitory paracrine crosstalk. We also discuss the impact of diabetes mellitus on somatostatin secretion and the role of somatostatin in the pathophysiology of the disease. Finally, we consider the δ-cell and somatostatin signalling as pharmacological targets for the treatment of diabetes mellitus.
Discovery of somatostatin and δ-cells Somatostatin was originally isolated from the hypothalamus and was found to inhibit the release of growth hormone (GH) in the pituitary 19 . Initially named GH release-inhibiting hormone, it was subsequently renamed somatostatin to reflect this growth-inhibiting effect. Shortly after its discovery, somatostatin was found to also be produced and secreted in the islets of Langerhans 20 .
The different endocrine cells of the islets were first identified on the basis of their histological staining properties. Glucagon-containing A-cells were identified by alcohol-based fixation methods whereas the insulinproducing B-cells were stained by aqueous-based fixation methods. In addition, a third type of islet cell was found unstained by either fixation method and was referred to as clear or C-cells. Later, using a different staining method (the Mallory-Heidenhain azan trichrome technique), a third type of granulated cell, in addition to the A-cells and B-cells, was identified and was referred to as D-cells (because the name C-cell was already taken). However, it is now clear that C-cells were in fact D-cells, but the nomenclature has not been changed, and the third most abundant cell type in pancreatic islets is still referred to as the D-cell. The history of islet histology and how it was eventually possible to correlate histological staining properties to hormone content is the subject of a recent review 21 , which readers interested in this fascinating topic are encouraged to consult. In this Review, we will refer to the different islet cells using the Greek letter nomenclature. Thus, the A-cells, B-cells and D-cells are referred to as α-cells, β-cells and δ-cells, respectively.
Somatostatin
There are two main forms of somatostatin -also known as somatotropin release inhibitory factor (SRIF) -in the body: somatostatin 14 (or SRIF14) and somatostatin 28 (or SRIF28) 22 . Both forms of somatostatin are derived from the precursor pre-prosomatostatin (116 amino acids in length), which is cleaved into prosomatostatin (92 amino acids). Prosomatostatin undergoes carboxyterminal post-translational processing to generate somatostatin 14 and somatostatin 28. Both peptides are very short-lived and have a half-life of 1 min in the circulation. Whereas somatostatin 28 is the dominant isoform elsewhere in the gastrointestinal tract, the pancreatic δ-cells secrete somatostatin 14.
The pancreatic δ-cells The δ-cells comprise only 5% of the islet cell population 4 . In mouse islets, the α-cells and β-cells occupy the islet periphery and core, respectively. Most of the δ-cells are located in the islet cortex with a few δ-cells found in the islet centre 23 . Whereas most α-cells and β-cells are rounded or rhomboid, the δ-cells show a more complex cellular morphology and have long, neurite-like processes (Fig. 1a) . These processes make close contact with α-cells, β-cells and other δ-cells located at some distance from the cell body, thereby enabling an extensive paracrine network. The neurite-like processes can be >20 μm long (one-third of the average islet diameter 24 ) and might influence multiple α-cells and β-cells via paracrine effects. This network might explain the stimulation of both glucagon and insulin secretion observed in the presence of somatostatin receptor antagonists [25] [26] [27] [28] . However, paracrine signalling (via intercellular diffusion of hormones) is not the only means of communication between islet cells. The β-cells are electrically connected via gap junctions [29] [30] [31] . Thus, a δ-cell might influence β-cells that are not in direct physical contact via changes in electrical activity in intermediary cells. There is also experimental evidence for electrical coupling between β-cells and δ-cells 32 .
In human pancreatic islets, the cellular architecture is less defined than in mice, with δ-cells located throughout the islet. Direct δ-cell to α-cell contacts are increased in islets from patients with type 2 diabetes mellitus 23 , raising the interesting possibility that the α-cells might be subjected to stronger somatostatin-mediated paracrine inhibition in such patients.
Gastric and enteric D-cells
Somatostatin is also expressed throughout the gastrointestinal tract; these somatostatin-secreting cells are referred to as D-cells. The gastrointestinal D-cells are estimated to be responsible for 65% of total body somatostatin, the pancreatic islets account for only 5% and the remaining amount is from the central nervous system 33 . Although the gastrointestinal D-cells
Key points
• The δ-cells of the pancreatic islets secrete somatostatin, a powerful paracrine inhibitor of both insulin and glucagon secretion from islet α-cells and β-cells. • δ-Cells are electrically excitable, and glucose stimulates action potential firing and somatostatin secretion by both metabolic and non-metabolic effects.
• Factors (such as GABA and urocortin 3) released by the β-cells stimulate somatostatin secretion, thereby providing a mechanism for feedback control of insulin and glucagon secretion during hyperglycaemia.
• Diabetes mellitus is associated with impaired glucagon secretion in response to hypoglycaemia; this effect is corrected by somatostatin antagonists, suggesting that diabetes mellitus involves hypersecretion of somatostatin during hypoglycaemia.
• Agents that inhibit somatostatin secretion or action might reduce the risk of insulin-induced hypoglycaemia and should be considered as an adjunct to insulin therapy.
are notoriously difficult to study as they are scattered among the enterocytes, it is now possible to isolate sufficient numbers of D-cells to perform more comprehensive transcriptomic analysis and physiological characterization 28 . However, the regulation of somatostatin secretion from the gastrointestinal D-cells is beyond the scope of this Review, and interested readers are instead referred to two reviews that cover aspects of this topic 34, 35 .
Islet somatostatin secretion
The regulation of somatostatin secretion in response to nutrient intake, in general, resembles that of insulin secretion. This similarity is perhaps not surprising as β-cells and δ-cells share an immediate common progenitor cell 36 . The regulation of somatostatin secretion by nutrient intake, pharmacological agents, hormones and neurotransmitters is shown in Fig. 1b . Further details about membrane receptors expressed in pancreatic δ-cells and their respective ligands are shown in Table 1 . In the following sections, we consider how δ-cells sense nutrients and correlate the regulation of glucagon secretion with the latest published δ-cell transcriptome data 37, 38 .
Glucose
In mouse islets, glucose-induced somatostatin secretion is initiated at glucose concentrations as low as 3 mM, and stimulation is half-maximal at glucose concentrations of 5-6 mM (Fig. 1c) . A similar, but not identical, glucose dependence is observed in human islets 39 . δ-Cells express high levels of high-affinity glucose transporter type 1 (GLUT1; also known as solute carrier family 2, facilitated glucose transporter member 1, which is encoded by Slc2a1) and type 3 (GLUT3; encoded by Slc2a3). δ-Cells also express high levels of glucokinase (encoded by GCK), which explains the inhibition of somatostatin secretion by the glucokinase inhibitor mannoheptulose 40, 41 . As will be discussed later in this Review, it is likely that the stimulatory effects of glucose are, at least in part, mediated by an increase in the cytoplasmic ATP:ADP ratio.
Amino acids
Somatostatin secretion can be stimulated by the amino acids leucine and arginine [42] [43] [44] [45] . The ability of arginine to stimulate somatostatin secretion probably reflects the expression of the high-affinity cationic amino acid transporters 1 (CAT1) and 2 (CAT2), which are encoded by SLC7A1 and SLC7A2, respectively 37, 38 . In β-cells, these transporters mediate electrogenic uptake of amino acids such as arginine and lysine 46 , which causes membrane depolarization and initiates action potential firing when K ATP channel activity is reduced (for example, in the presence of glucose). Arginine probably stimulates somatostatin secretion by the same mechanism.
Leucine is transported via the large neutral amino acid transporter small subunit 1 (SLC7A5), which is expressed in δ-cells 37, 38 . Following deamination and the formation of α-ketoisocaproic acid 47 , leucine is metabolized in the Krebs cycle and probably stimulates somatostatin secretion by a glucose-like mechanism mediated by an increased cytoplasmic ATP:ADP ratio.
Fatty acids
The plasma concentration of non-esterified free fatty acids (mainly palmitate, oleate, stearate and lineoleate 48 ) fluctuates between <0.1 mM after a meal and 0.5-1.0 mM in the fasted state 3 . Palmitate inhibits glucose-induced somatostatin secretion 49 . Mouse δ-cells express high levels of the free fatty acid receptor 4 (also known as G-protein coupled receptor 120 (GPR120)), which is encoded by FFAR4. Interestingly, GPR120-specific agonists inhibit somatostatin secretion, and these effects are absent in islets from Ffar4-knockout mice 50 . This selective inhibition of the δ-cells could be expected to result in the removal of the paracrine suppression of α-cells and β-cells exerted by somatostatin, which might contribute to the acute palmitate-induced stimulation Here, 100% and 0% correspond to the maximum and the minimum secretion, respectively. The grey shading highlights that glucose exerts most of its inhibitory effect on glucagon secretion at concentrations up to 5 mM and that this is associated with some modest stimulation of somatostatin secretion. GLP1, glucagon-like peptide 1; GPR120, G protein-coupledreceptor120;M3,muscarinicacetylcholinereceptor3;NEFAs, non-esterifiedfreefattyacids;SERCA ,sarcoplasmic/endoplasmicreticulum Ca² + -ATPase; SSTR , somatostatin receptor.
of both insulin and glucagon secretion 49, 51 . Conversely, free fatty acid-induced suppression of somatostatin secretion might ensure adequate glucagon secretion in the fasted state (when circulating free fatty acid levels are high).
δ-Cell electrophysiology
Similar to α-cells and β-cells, δ-cells are electrically excitable, and glucose-induced somatostatin secretion is associated with stimulation of action potential firing 27 ( Fig. 2a) . The K ATP channels expressed in δ-cells are exactly the same as those found in α-cells and β-cells. Expression levels of the K ATP subunits ATP-sensitive inward rectifier K + channel 11 (Kir6.2; encoded by KCNJ11) and sulfonylurea receptor 1 (SUR1; which is encoded by ABCC8) in δ-cells are similar to those in β-cells 37, 38 . The K ATP channels are active (open) at low concentrations of glucose, and this maintains a negative (hyperpolarized) membrane potential in the δ-cells. Glucose causes the K ATP channels to close, makes the δ-cell membrane potential more positive (depolarization) and initiates action potential firing with resultant stimulation of somatostatin secretion 40, 42, [52] [53] [54] . Pharmacological blockers of K ATP channels (such as the sulfonylureas glibenclamide and tolbutamide) have the same effect. Conversely, the K ATP channel activator diazoxide prevents depolarization and thereby inhibits somatostatin secretion 55, 56 . The K ATP channel activity is lower in δ-cells than in β-cells, which might explain why somatostatin secretion is initiated at lower glucose concentrations than insulin secretion 57 . The stimulus-secretion coupling for the δ-cell, outlined previously, is similar to what has been described in β-cells 24 . Therefore, it is surprising that the nonmetabolizable glucose analogue 3-O-methyl-D-glucose also stimulates somatostatin secretion 58 (an effect unlikely to be mediated via an increase in the intracellular ATP:ADP ratio). Thus, it appears that glucose could stimulate somatostatin secretion by a mechanism not involving the closure of K ATP channels. Some evidence suggests that there is low expression of sodium-glucose cotransporter 1 (SGLT1; encoded by Slc5a1) in δ-cells 37, 38 . Therefore, the ability of 3-Omethyl-D-glucose to stimulate somatostatin secretion might be secondary to the electrogenic (that is, the ability to change the membrane potential) uptake of this glucose analogue, and this, in some δ-cells with particularly low K ATP channel activity, suffices to trigger an electrical signal and somatostatin secretion. SGLT1 will also transport D-glucose, but its contribution to total glucose uptake in pancreatic δ-cells is likely to be small as its expression is low compared with that of GLUT1 and GLUT3.
In mouse δ-cells, the action potential originates from a membrane potential as low as -60 mV, peaks at +30 mV and has a duration of only a few milliseconds 59 (Fig. 2b) .
The different voltage-gated ion channels contributing to the action potential in the mouse pancreatic δ-cell were determined by electrophysiology 59 and transcriptomic )
. RPKM values provide a useful approximation of actual receptor expression levels, but many post-transcriptional processes contribute to the actual cell surface expression of receptor protein.
studies 37, 38 . The action potential is initiated by the opening of low-threshold T-type Ca 2+ channels (specifically the voltage-dependent T-type Ca 2+ channel subunit α 1H ; also known as Ca V 3.2). The T-type Ca 2+ channels depolarize the δ-cell to -45 mV, which is the threshold for the activation of voltage-gated Na + channels (Na + channel protein type 3 subunit α and/or type 9 subunit α; also known as Na V 1.3 and/or Na V 1. 27, 59 . High glucose initiates action potential firing that is suppressed by tetrodotoxin (TTX; grey box). b | Schematic of the contribution of different ion channels to δ-cell electrical activity. c | Stimulus-secretion coupling in a mouse δ-cell. Glucose uptake via glucose transporter type 1 (GLUT1) and type 3 (GLUT3) stimulates glucose metabolism, increases the cytoplasmic ATP:ADP ratio and inhibits K ATP channels. , with some contribution from delayed rectifying K + channels (specifically K + voltage-gated channel subfamily A member 5 and subfamily B member 1; also known as K V 1.5 and K V 2.1, respectively). Membrane repolarization of the action potential also results from the inactivation of the voltage-gated Na + channels and T-type and L-type Ca 2+ channels. In the interval between two successive action potentials, the K V 1.5 and K V 2.1 channels that activated during the action potential deactivate slowly, and this, together with the recovery from the inactivation of Na + channels and T-type and L-type Ca 2+ channels, explains the slow depolarization between two successive action potentials. Single-cell transcriptomic analysis 60 indicates a similar ion channel complement in human δ-cells.
Modulators of somatostatin secretion
In addition to the direct effects of glucose (and other nutrients) on δ-cells, somatostatin secretion is modulated by paracrine factors (released from neighbouring α-cells and β-cells), circulating hormones and neurotransmitters released by intra-islet nerve endings ( Fig. 1b; Table 1 ).
Intra-islet factors
Insulin. Pancreatic δ-cells express insulin receptors (encoded by INSR), but the action of insulin on somatostatin secretion is unclear. Anterograde infusion (that is, in the direction of normal blood flow) of an anti-insulin antibody (to immuno-neutralize endogenous insulin) leads to a dramatic 20-fold increase in stimulation of somatostatin secretion 61 . Administration of exogenous insulin has variably been reported not to affect 62 , inhibit 45 or stimulate somatostatin secretion 63 . These variable results might be a consequence of different experimental conditions (such as isolated islets versus perfused pancreas). It should be remembered that the intra-islet interstitial insulin concentration is probably very high; a single insulin granule contains 1.6 × 10 −18 mol insulin, and releasing this is sufficient to increase the interstitial insulin concentration between the islet cells to ~10 nM, which is >100-fold higher than circulating levels of insulin 24 .
Glucagon. The δ-cells also express low levels of glucagon receptor (encoded by GCGR) and respond to glucagon with increased somatostatin secretion 43, 64 , presumably by stimulation of cAMP production (described later in this Review). UCN3) is a 38-amino-acid peptide that is a member of the corticotropin-releasing hormone (CRH) family 65 . Urocortin 3 is co-released with insulin from β-cells and stimulates somatostatin secretion 55 . Urocortin 3 activates the α-isoform of the corticotropin-releasing factor receptor 2 (CRHR2; encoded by Crhr2), which is selectively expressed by δ-cells within the islet 55 . In mice, genetic ablation of Crhr2 or Ucn3 leads to a 50-60% reduction of glucose-induced somatostatin secretion, an effect that was paralleled by a corresponding decrease in islet somatostatin content. By activating the CRHR2 receptor, urocortin 3 stimulates production of cAMP, which probably accounts for the stimulation of somatostatin secretion. Collectively, these observations indicate that islet somatostatin secretion is modulated by local release of urocortin 3 from β-cells.
Urocortin 3. Urocortin 3 (encoded by

GABA.
The neurotransmitter GABA is also co-released with insulin from β-cells and stimulates somatostatin secretion in human islets 66 . GABA co-released with insulin and urocortin 3 might contribute to glucoseinduced somatostatin secretion. In addition, evidence suggests that GABA released from human δ-cells depolarizes the δ-cell and stimulates electrical activity in an autocrine fashion 66 . Expression of GABA receptor subunits is low in mouse δ-cells (Table 1) , but electrophysiological measurements suggest that expression in human δ-cells is high. Thus, large Cl − currents are evoked by application of GABA to human δ-cells that can be blocked by the GABA A receptor antagonist SR-95531 (reF. Acetylcholine. In mouse islets, acetylcholine is released by cholinergic nerve endings 67 . The reported actions of acetylcholine on somatostatin secretion are conflicting as it has variably been found to stimulate 40 or inhibit 50, 53 somatostatin secretion. Mouse δ-cells express muscarinic acetylcholine receptors M3 (encoded by Chrm3) and M4 (encoded by Chrm4). The M3 receptors are coupled to the guanine nucleotidebinding protein G q subunit, which leads to Ca 2+ mobilization and stimulation of somatostatin exocytosis, whereas the M4 receptors are coupled to the guanine nucleotide-binding protein G i subunit, which results in the suppression of somatostatin secretion. Thus, expression of these two muscarinic receptors, coupled to different canonical signalling cascades, might explain the contradictory effects of acetylcholine action on somatostatin secretion.
Endocrine modulators GLP1 and gastric inhibitory polypeptide. δ-Cells express GLP1 receptors (encoded by GLP1R) and low levels of gastric inhibitory polypeptide (GIP) receptors (encoded by GIPR). Predictably, somatostatin secretion is stimulated by the incretin hormones GLP1 (and its agonists), GIP and agents that increase cAMP (such as forskolin) 62, 68, 69 . How cAMP stimulates somatostatin secretion is discussed later in this Review.
Adrenaline. Of the adrenergic receptors, only α 2A receptors (encoded by Adra2a) are expressed at notable levels in δ-cells. The α 2A receptor is also responsible for the direct inhibition of insulin secretion (by activation of G i ) in response to direct adrenergic inputs to β-cells and probably also accounts for the reported inhibitory effects of adrenaline on somatostatin secretion 53, 70 .
Ghrelin. The hunger hormone ghrelin is known to inhibit insulin secretion. Many different and sometimes conflicting mechanisms have been proposed to explain how the ghrelin receptor, which acts via the guanine nucleotide-binding protein G q subunit α (G αq ) and thus would be predicted to stimulate intracellular Ca 2+ release and stimulate secretion, actually inhibits insulin release. This conundrum was resolved with the discovery that ghrelin receptors (encoded by GHSR) are selectively expressed in δ-cells, where they mediate robust and selective secretion of somatostatin from mouse and human islets in response to ghrelin, which inhibits insulin release by a paracrine mechanism 37, 38 .
Ca
2+
-regulated somatostatin secretion Glucose-induced somatostatin secretion is associated with an elevation of intracellular levels of Ca 2+ ([Ca   2+ ] i ). In isolated mouse δ-cells, large [Ca 2+ ] i oscillations are observed at glucose levels as low as 3 mM (reF. 71 ).
Glucose-induced [Ca 2+ ] i oscillations are also observed in δ-cells in intact islets at 3 mM glucose 72 . These fluctuations were suppressed by lowering glucose concentrations to 0.5 mM or by the addition of the K ATP channel activator diazoxide 73 . Membrane depolarization, caused by supraphysiological levels of extracellular K + (box 1), also increases [Ca 2+ ] i and stimulates somatostatin secretion 38, 40, 71, 74 . This effect is mediated by the opening of voltage-gated Ca 2+ channels (VGCCs) and is inhibited by Ca 2+ channel blockers such as isradipine and SNX-482 (reFs 40, 55 ).
The nature of the glucose-induced [Ca 2+ ] i oscillations has not been conclusively established, but it is possible that they involve in part the mobilization of intracellular Ca 2+ . The strong inhibitory effects of thapsigargin, dantrolene and ryanodine on glucoseinduced somatostatin secretion 40 indicate an important role that intracellular Ca 2+ stores have in somatostatin secretion. Dantrolene and ryanodine are inhibitors of the intracellular ryanodine receptors (RyRs; encoded by Ryr1, Ryr2 and Ryr3), which are Ca 2+ -release channels in the sarcoplasmic reticulum, and thapsigargin is an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase (SERCA). Collectively, these findings suggest a crosstalk between plasmalemmal and intracellular Ca 2+ channels and that Ca 2+ entry via the VGCCs might result in an additional increase in [Ca 2+ ] i by the activation of Ca 2+ -induced Ca 2+ release (CICR) mediated by RyR (Fig. 2c) . In mouse islets, RyR expression is almost exclusively restricted to δ-cells, and RyR3 is the dominant subtype 37, 38 . Thus, any effects of ryanodine on insulin and glucagon secretion might reflect a paracrine effect (Fig. 3a) .
The CICR-dependent component of somatostatin secretion is small at low levels of glucose but increases with rising levels of glucose (being half-maximal at ~10 mM) 40 . Glucose-induced somatostatin release is nearly abolished by inhibitors of protein kinase A and the cAMP sensor exchange protein directly activated by cAMP 2 (Epac2; also known as RAPGEF4) (P.R., unpublished observations). cAMP might promote CICR by sensitizing RyR3 to Ca 2+ (reF. 75 ). How glucose increases intracellular levels of cAMP and promotes CICR is not known, but it might be the result of paracrine signalling within the islets. For example, release of urocortin 3 and glucagon from neighbouring α-cells and β-cells might activate adenylyl cyclase and increase cAMP upon binding to the glucagon and CRHR2 receptors, respectively.
Somatostatin as a paracrine regulator
Once somatostatin has been released from δ-cells, it exerts local paracrine effects by activation of somatostatin receptors (SSTRs) in other islet cells. Whether somatostatin secreted by pancreatic islets also exerts other systemic effects is not known, but quantitative considerations suggest that such effects are unlikely to be of major functional importance. First, only 5-10% of somatostatin in plasma is somatostatin 14 (the δ-cell variety of somatostatin) 76 . Second, pancreatectomy (the surgical removal of the pancreas with removal of all pancreatic δ-cells) does not lower plasma levels of somatostatin 77 . Studies in dogs indicate that a glucose-induced stimulation of somatostatin secretion could be detected only in the pancreatic vein (that drains the pancreas) and that the somatostatin concentration changes little (if at all) in the vena cava and mesenteric vein (that drain the gut) 78 .
There are five different somatostatin receptors (SSTR1-SSTR5) 79 . All the SSTRs couple to an inhibitory G protein (G i ), and the effects of somatostatin can be prevented by pretreatment with pertussis toxin 79 . Transcriptomic analyses using RNA sequencing on fluorescence-activated cell sorting (FACS)-purified islet cell populations confirm that SSTR2 and SSTR3 are the In most cells, K + channel activity represents the dominant ionic permeability. In β-cells and δ-cells, the resting K + permeability at low glucose is provided by K ATP channels. As K + are positively charged, K + channel activity down a concentration gradient will generate an excess of negative charges inside the cell. K + will continue to exit the cell until the electric field across the plasma membrane exactly balances the concentration gradient (the equilibrium or Nernst potential (E K )). The Nernst equation (presented below) allows this membrane potential to be estimated for different extracellular and intracellular K + concentrations. predominant receptor subtypes in mouse and human α-cells, whereas β-cells predominantly express SSTR3
(reFs 37, 38, 80 ) (Fig. 3a) . Somatostatin exerts a plethora of effects on both α-cells and β-cells, which collectively result in reduction of insulin and glucagon secretion (Fig. 3b) . Thus, somatostatin reduces the activity of adenylyl cyclase, resulting in lower cytoplasmic cAMP ([cAMP] i ) 81 and less cAMP-induced exocytosis, inhibits VGCCs and activates G protein-activated inward rectifier K + channel (GIRK), which causes membrane repolarization and suppression of action potential firing 82, 83 . In addition, somatostatin exerts a direct inhibitory effect on exocytosis independent of [cAMP] i that might involve activation of the protein phosphatase calcineurin 83, 84 . Interestingly, mouse δ-cells express SSTR1 as well as SSTR3 (reFs 37, 38 ), possibly suggesting somatostatin release is under autocrine feedback control, which may account for the strong stimulation of 81 and less cAMP-induced exocytosis; inhibition of voltage-gated Ca 2+ channels (VGCC); activation of G protein-activated inward rectifier K + channel (GIRK), which causes membrane repolarization and inhibition of electrical activity 82, 83 ; and a direct inhibitory effect on exocytosis somatostatin secretion in the presence of somatostatin receptor antagonists 68, 85 . In addition to the inhibitory effects of somatostatin on hormone release, somatostatin also influences β-cell mass. Somatostatin agonists are potent suppressors of neuroendocrine tumour growth 86 and inhibit the proliferation of MIN6 insulinoma cells 87 as well as mouse and human β-cells 88 . These results are in agreement with the observation that G i signalling inhibits β-cell proliferation 89 . However, mice with no somatostatin gene expression do not demonstrate increased β-cell mass 53 , but it is possible that any stimulation of β-cell proliferation was offset by a reduced transdifferentiation of δ-cells to β-cells 90 .
Somatostatin and diabetes mellitus
Diabetes mellitus (both type 1 and 2) is considered a bihormonal disorder involving defects in both insulin and glucagon secretion 91 . Given that somatostatin inhibits insulin and glucagon secretion, the question arises as to whether diabetes mellitus might involve all three major islet hormones.
Studies in rats and dogs with diabetes mellitus indicate that somatostatin secretion at low levels of glucose is higher than in control animals with no diabetes mellitus and was not stimulated by high levels of glucose [92] [93] [94] . There is no published information on the impact of diabetes mellitus on somatostatin secretion in isolated human islets. Measurements of circulating somatostatinlike immunoreactivity indicate that whereas a mixed meal increases circulating somatostatin-like immunoreactivity by 10% in healthy individuals, it is increased by 20% in patients with type 2 diabetes mellitus 95 (but as discussed previously, only a fraction of this reflects somatostatin 14 originating from δ-cells).
Therapeutic implications
A most important question is whether the δ-cells and somatostatin secretion could be pharmacologically targeted to provide benefits to patients with diabetes mellitus. The risk of hypoglycaemia constitutes a barrier to good glycaemic control, and many insulin-dependent patients with diabetes mellitus are treated less aggressively with insulin than would otherwise be the case in order to reduce the risk of hypoglycaemia 96 . In fact, a U-shaped relationship exists between plasma levels of glucose and mortality in patients with diabetes mellitus, with the lowest mortality in patients with diabetes mellitus who have HbA 1C levels of 7.5% (a surrogate marker of long-term glycaemic control) 97 , which is well above that typically seen in individuals who do not have diabetes mellitus (≤5%) 98 . It is likely that at least part of the increase in mortality at HbA 1C values below 7.5% is caused by hypoglycaemia.
As discussed previously in this Review, experiments in rat models of diabetes mellitus are suggestive of impaired counter-regulatory glucagon secretion during insulin-induced hypoglycaemia due to increased somatostatin signalling [12] [13] [14] . The consequences of somatostatin oversecretion under hypoglycaemic conditions might be corrected by preventing its biological effects. Indeed, SSTR2 antagonists restore counter-regulatory glucagon secretion during insulin-induced hypoglycaemia in rats with diabetes mellitus [12] [13] [14] . However, these receptors are widely expressed (for instance, in the stomach, adrenal medulla, cerebral cortex and hypothalamus) 99 ; therefore, translation to human studies requires safety testing. A radiolabelled SSTR2 antagonist (JR11) is being used in clinical trials 100 , which will provide information on safety and tolerability.
When considering the therapeutic implications and the risk of hypoglycaemia, it is worth remembering that insulin produces not only hypoglycaemia but also a long-lasting reduction of the plasma concentration of K + (hypokalaemia) 101 . Hypokalaemia is associated with increased mortality 102 , possibly via cardiac effects 103 . In general, hypokalaemia decreases electrical excitability in cells. This effect is caused by lowered extracellular K + levels, which generally lead to membrane hyperpolarization (box 1), with resultant reduction of cellular activity (secretion, nerve activity and muscle contraction). Therefore, it is paradoxical that hypokalaemia stimulates rather than inhibits somatostatin secretion 104 . The stimulation of somatostatin secretion was attributed to inhibition of the Na + /K + -ATPase. The Na + /K + -ATPase is electrogenic, and for every ATP hydrolysed, three Na + and two K + are transported across the cell membrane in opposing directions, leading to a net loss of a positive charge inside the cell. Thus, the normal operation of the Na + /K + -ATPase tends to repolarize the membrane potential. In addition, the activity of the pump might lower the submembrane ATP:ADP ratio, thus increasing K ATP channel activity and repolarizing the δ-cell. Inhibition of the Na + /K + -ATPase by lowering extracellular levels of K + may thus depolarize the δ-cell by dual effects: it removes the repolarizing influence of the Na + /K + -ATPase and inhibits K ATP channel activity by exerting an ATP-sparing effect (Fig. 3c) . It has been estimated that the Na + /K + -ATPase accounts for up to 50% of energy expenditure 105 . Collectively, these effects stimulate somatostatin secretion. This stimulation might culminate in impaired counter-regulatory hepatic glucose production during acute insulin-induced hypoglycaemia by suppression of glucagon secretion.
Conclusion
In this Review, we have attempted to illustrate the important roles played by pancreatic δ-cells and somatostatin in health and disease. It is clear that the pancreatic islets are very complex structures and that via paracrine crosstalk, the islets are much more than the 'sum of the parts' . The δ-cells are emerging as master regulators within the islets and represent an interesting and novel pharmacological target through which dysregulated insulin and glucagon secretion in diabetes mellitus might be corrected. Indeed, by virtue of their capacity for restoring counter-regulatory glucagon secretion, SSTR2 antagonists should be considered as an adjunct to insulin therapy, thereby enabling more aggressive insulin treatment by minimizing the risk of hypoglycaemia.
